Kenmochi Toya Real Solo Live "KOKU FES." Live Viewing Confirmed!
Press Release

Kenmochi Toya Real Solo Live "KOKU FES." Live Viewing Confirmed!

TOKYO, Sept. 28, 2026 /PRNewswire/ — Kenmochi Toya, one of the longstanding VTubers of NIJISANJI, is here to captivate audiences with his solo live concert, "Kenmochi Toya Real Solo Live【KOKU FES.】"taking place on Sunday, October 11, 2026, at K-Arena Yokohama. Joined by special guests Kuzuha, Peanuts-kun, and Hoshimachi Suisei, the highly anticipated concert will be […]

Read More
Kuzuha One-Man Live "Bloody Alexandrite" Live Viewing Confirmed!
Press Release

Kuzuha One-Man Live "Bloody Alexandrite" Live Viewing Confirmed!

TOKYO, Sept. 28, 2026 /PRNewswire/ — Kuzuha, one of NIJISANJI’s most prominent VTubers, is set to take the stage once again for his third solo live concert, "Kuzuha One-Man Live ‘Bloody Alexandrite’" taking place on Monday, October 12, 2026 at K-Arena Yokohama. Joined by special guests Kenmochi Toya, Fuwa Minato, Ibrahim, and Lauren Iroas, the highly […]

Read More
Jining welcomes global guests for Confucius festival, Nishan Forum
Press Release

Jining welcomes global guests for Confucius festival, Nishan Forum

QUFU, China, Sept. 28, 2026 /PRNewswire/ — Confucius (551–479 BC) may have lived 2,500 years ago, but his ideas are drawing fresh global attention this autumn. The 2026 China International Confucius Cultural Festival and the 2026 Nishan Forum on World Civilizations both opened in Qufu, Jining, Shandong province, on Sept 28, bringing together scholars, officials, […]

Read More
Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme
Press Release

Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme

The Collinson Group recently announced £350m in new financing, which will accelerate the £500 million growth strategy; reflective of both strong confidence in the Group’s performance and its commitment to driving innovation and leadership in airport experiences.  A core focus will be acceleration of the digital roadmap, leveraging new data and AI capabilities, and significantly expanding […]

Read More
Agoda Brews Up Six Asian Escapes for Coffee-Loving Travelers
Press Release

Agoda Brews Up Six Asian Escapes for Coffee-Loving Travelers

SINGAPORE, Sept. 28, 2026 /PRNewswire/ — Coffee is becoming more than a morning ritual. For many travelers, it is now a way to understand a place, from the beans grown on nearby hills to the cafés where locals meet, work and linger over a slow pour. The rise of independent roasters, specialty coffee and social-media […]

Read More
PR Newswire Launches AEO & GEO Report for AI Brand Visibility in APAC Region
Press Release

PR Newswire Launches AEO & GEO Report for AI Brand Visibility in APAC Region

Brand-level AI visibility intelligence empowers PR, marketing and investor relations teams to actively command their brand presence across the generative search landscape with a single end-to-end amplification platform. HONG KONG, Sept. 28, 2026 /PRNewswire/ — AI-powered search and generative answer engines are reshaping how audiences discover and evaluate brands, and communicators are increasingly seeking data-driven […]

Read More
Metaverse Lab-XR: Virtual Lab Builds Diagnostic and Teamwork Skills for Medical Technology Students
Press Release

Metaverse Lab-XR: Virtual Lab Builds Diagnostic and Teamwork Skills for Medical Technology Students

A Chula Medical Technology lecturer has developed Metaverse Lab-XR, an innovative virtual laboratory that allows students to practice lab procedures and develop the soft skills needed for real-world work in hospitals, preparing them to become skilled and knowledgeable medical technologists. BANGKOK, Sept. 28, 2026 /PRNewswire/ — For Medical Technology students, laboratory skills are just as important […]

Read More
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
Press Release

Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer

HONG KONG, Sept. 28, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy versus chemotherapy with or without nivolumab as first-line treatment for patients […]

Read More

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.